Interventional device firm ev3 of Plymouth, MN, has completed its purchase of Redwood City, CA-based FoxHollow Technologies, the company said.
FoxHollow is now a wholly owned subsidiary of ev3. The two companies' combined product portfolio will include products to treat vascular disease in both the peripheral and neurovascular markets, including atherectomy and thrombectomy, PTA balloons, stents, embolic protection devices, infusion catheters and wires, embolic coils, and liquid embolics.
The combined company's ownership consists of 41% FoxHollow shareholders and 59% ev3 shareholders. Ev3 will add four of FoxHollow's former directors to its board.
By AuntMinnie.com staff writers
October 5, 2007
Related Reading
ev3 reports Q1 double-digit sales growth, secondary offering, April 3, 2007
ev3 gets FDA approval for Protege RX, January 25, 2007
ev3 stent gets FDA, CE nods for Protégé, March 10, 2006
ev3 stent gets 510(k), October 21, 2004
Copyright © 2007 AuntMinnie.com
